Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Intraocular Lymphoma × zanubrutinib × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Large B-Cell, Diffuse 29 Leukemia, Lymphocytic, Chronic, B-Cell 25 Lymphoma, Mantle-Cell 24 Lymphoma, Follicular 14 Waldenstrom Macroglobulinemia 13 Lymphoma, B-Cell, Marginal Zone 12 Recurrence 11 Lymphoma 9 Lymphoma, B-Cell 7 Lymphoma, Non-Hodgkin 5 Leukemia 3 B-cell Malignancies 3 Neoplasms 2 Multiple Myeloma 1 Mature B-Cell Malignancies 1 Lymphohistiocytosis, Hemophagocytic 1 Leukemia, B-Cell 1 Intraocular Lymphoma 1 Hematologic Neoplasms 1 Hematologic Diseases 1 Dendritic Cell Sarcoma, Interdigitating 1 Congenital Abnormalities 1

Interventions

Rituximab 12 Cyclophosphamide 11 Peripheral Blood Stem Cell Transplantation 10 fludarabine phosphate 8 Filgrastim 8 Cyclosporine 8 Whole-Body Irradiation 7 Methotrexate 7 Etoposide 7 Mycophenolic Acid 6 Lenalidomide 6 Radiotherapy 5 Cytarabine 5 Tacrolimus 4 Dexamethasone 4 Antilymphocyte Serum 4 Vorinostat 3 Thiotepa 3 Melphalan 3 Granulocyte Colony-Stimulating Factor 3 Dasatinib 3 Carboplatin 3 Busulfan 3 Bortezomib 3 tanespimycin 2 pegfilgrastim 2 laromustine 2 ibrutinib 2 etoposide phosphate 2 entinostat 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06973811 2025-05-20

ZR-MTX

Peking Union Medical College Hospital

Phase 2 Not yet recruiting

Intraocular Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡